Items Tagged ‘Prostate Cancer’

July 17, 2018

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

By

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC (NM-CRPC) and metastatic CRPC. Xtandi was previously approved for the treatment of patients with metastatic CRPC. About Prostate Cancer Prostate cancer is […]

View full entry

Tags: News, Prostate Cancer


May 1, 2018

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer

By

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate cancer who are unable to receive more aggressive treatment. Some experts believe that ADT should be […]

View full entry

Tags: androgen deprivation therapy, hormone therapy, Immediate vs Delayed, News, Prostate Cancer


February 22, 2018

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer?

By

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that the use of Xtandi® (enzalutamide) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71 […]

View full entry

Tags: adt, androgen deprivation therapy, castration-resistant prostate cancer, crpc, enzalutamide, News, Prostate Cancer, PSA, rising prostate specific antigen, xtandi


February 19, 2018

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer

By

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada (Apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).1  There were previously no FDA-approved treatments for […]

View full entry

Tags: Apalutamide, Erleada, News, non-metastatic castration-resistant prostate cancer, Prostate Cancer, rising psa, treatment


February 14, 2018

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation

By

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif.  The key finding is that more than 12 percent of men with prostate cancer had an inherited (i.e. […]

View full entry

Tags: Genetics, germline mutations, Hereditary Caner Test, hereditary risk, myRisk, News, Prostate Cancer


September 8, 2017

Two Advances in Prostate Cancers You Might Not Know About

By

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means that both men and women need to be aware of their family history […]

View full entry

Tags: Afluria, Center for Disease Control, flu vaccine, Fluad, Fluarix, Flubolk, Flulaval, FluMist, Fluvirin, Fluzone, Fluzone High-Dose, Intradermal


March 9, 2016

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer

By

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual Genitourinary Cancers Symposium. Low-grade prostate cancer refers to cancer that has not spread to distant sites in […]

View full entry

Tags: clinical trial, hypofractionated, Prostate Cancer, radiation


April 28, 2011

Intermittent Hormone Therapy Effective for Prostate Cancer

By

For men who experience a PSA recurrence (rise in prostate-specific antigen levels) after radiation therapy for prostate cancer, hormone therapy given intermittently (with breaks) appears to be as effective as hormone therapy given continuously. These results were presented at the 2011 Genitourinary Cancers Symposium. Androgen deprivation therapy is designed to block testosterone from stimulating the […]

View full entry

Tags: Prostate Cancer, Refactory/Recurrent Prostate Cancer


November 30, 2010

Xgeva Approved for Patients with Bone Metastases

By

Xgeva™ (denosumab) has been approved by the US Food and Drug Administration (FDA) for the prevention of bone complications such as fracture in patients with bone metastases from solid (not blood-related) cancers. It is not approved for patients with multiple myeloma or other cancers of the blood. Metastatic cancer refers to cancer that has spread […]

View full entry

Tags: Breast Cancer, Management and Prevention of Bone Complications Supportive Care, Metastatic Breast Cancer, Metastatic Stage IV (D) Prostate Cancer, Prostate Cancer, Supportive Care


March 31, 2009

Supplementation with Folic Acid Associated with Increased Risk of Prostate Cancer

By

Supplementation with folic acid significantly increases the risk of prostate cancer, according to the results of a study recently published in the Journal of the National Cancer Institute.[1] The role of micronutrients in relationship to cancer incidence has become a major focus among researchers. Some dietary choices have been shown to reduce the risk of […]

View full entry

Tags: Prostate Cancer


March 31, 2009

Questions Remain About Benefit of PSA Screening for Prostate Cancer

By

Two randomized studies of prostate-specific antigen (PSA) screening for prostate cancer were recently published in the New England Journal of Medicine. One of the studies, conducted in Europe, reported that PSA screening decreased prostate cancer mortality by 20%. The other study, conducted in the United States, found that higher levels of PSA screening did not […]

View full entry

Tags: Prostate Cancer


March 19, 2009

Judith Giuliani: A Caregiver’s Perspective

By

Rudy Giuliani’s wife discusses her partnership with her husband during his prostate cancer journey and their team approach to the experience. By Diana Price Judith Giuliani knows a thing or two about healthcare. She is trained as a registered nurse, and her extensive medical and scientific background includes work for Bristol-Myers Squibb and special training […]

View full entry

Tags: Prostate Cancer


February 6, 2009

Cancer Vaccines: Stimulating the Immune System to Attack Cancer

By

As the age of personalized medicine approaches, the look and feel of cancer treatment may change dramatically. What if, rather than receiving one-size-fits all anticancer drugs, patients were treated with specially formulated treatments made to target their own cancer cells? What if patient’s own cancer and immune cells were actually used to develop a treatment […]

View full entry

Tags: Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Skin Cancer


February 6, 2009

Many Older Men with Early-stage Prostate Cancer May Be Able to Avoid Treatment

By

Among elderly men with early-stage prostate cancer, a majority of those who choose watchful waiting in place of immediate cancer treatment will not require treatment or will die of other causes before their cancer progresses significantly. These results were presented at the first Genitourinary Cancers Symposium, which was co-sponsored by the American Society of Clinical […]

View full entry

Tags: Prostate Cancer


February 6, 2009

Androgen Deprivation Benefits Some Patients with Early Prostate Cancer

By

Recently published studies suggest that the addition of androgen deprivation therapy to radiation therapy improves outcomes in subsets of men with early prostate cancer. Early prostate cancer refers to prostate cancer that has not spread from the prostate to distant sites in the body. Standard therapy for early prostate cancer may include surgery, radiation therapy, […]

View full entry

Tags: Prostate Cancer